Florence Cymbalista, MD, PhD and Michael Keating, MB, BS
In this segment, “Future Directions in CLL”, Florence Cymbalista, MD, PhD and Michael Keating, MB, BS discuss new therapies and knowledge gaps in CLL (chronic lymphocytic leukemia).
This is a very exciting time in CLL, as advances in biology and the genomic landscape are successfully translating to patient care. Multiple highly effective agents have become available, including targeted inhibitors of BCR signaling and anti-apoptotic BCL-2, as well as novel anti-CD20 antibodies. Treatment challenges remain, however, such as side effects and treatment sequence. Other unmet needs include validated tools for stratification of patients by genetic drivers and for detection of minimal residual disease.